Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1020
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $935 to $1020.
January 23, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has reaffirmed its Overweight rating on Regeneron Pharmaceuticals and raised the price target to $1020, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Carter Gould from Barclays is a strong positive signal to the market, suggesting a bullish outlook for Regeneron Pharmaceuticals. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100